Ayman Hamad, APRN
Nurse Practitioner · Wichita, KSNPI 1447218326
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,927 of the $9,175 with a category attached, or 86.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,555 and has fallen 99.6% since, to $20 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$1K
- Pfizer$627
- Novartis$625
- Johnson & Johnson$560
- plus $3K from 17 others
What the payments were for
- Travel & lodging$1,14412%
- Food & beverage$7,92786%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 30 | $2,056 |
| E.r. Squibb & Sons, L.L.C. | 194 | $1,265 |
| AstraZeneca(2 entities) | 24 | $1,066 |
| Pfizer | 86 | $627 |
| Novartis | 44 | $625 |
| Johnson & Johnson | 39 | $560 |
| Boehringer Ingelheim | 13 | $410 |
| Novo Nordisk | 6 | $396 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $293 |
| Bayer | 9 | $285 |
| Actelion Pharmaceuticals US, Inc. | 6 | $248 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $208 |
| Boston Scientific | 5 | $207 |
| Amgen | 9 | $198 |
| Merck | 10 | $176 |
| Abbott | 1 | $160 |
| Alnylam Pharmaceuticals Inc. | 3 | $136 |
| Amarin Pharma, Inc. | 4 | $84 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $66 |
| Cvrx, Inc. | 3 | $50 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,175 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $37,597 |
| EntrestoSacubitril/Valsartan | 12 | $7,952 |
| FarxigaDapagliflozin Propanediol | 12 | $7,389 |
| Potassium Chloride | 21 | $730 |
| Bumetanide | 19 | $530 |
| Amiodarone Hcl | 49 | $502 |
| Metoprolol Succinate | 33 | $486 |
| Losartan Potassium | 30 | $307 |
| ClopidogrelClopidogrel Bisulfate | 36 | $301 |
| Metoprolol Tartrate | 43 | $272 |
| Metolazone | 30 | $197 |
| Furosemide | 31 | $170 |
| Atorvastatin Calcium | 30 | $165 |
| Carvedilol | 19 | $161 |
| Nitroglycerin | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $627 | $37,59761 claims |
| NovartisEntresto | $625 | $7,95212 claims |
| AstraZenecaFarxiga | $1,066 | $7,38912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Wichita
- Constance JacobWichita$65K
- Catherine PowellWichita$50K
- Darine JamaleddineWichita$15K
- Krystal MitchellWichita$13K
- Jolene GrotheWichita$11K
- Christina StantonWichita$11K
- Sarah RookerWichita$10K
- Amanda MogoiWichita$9K
- Jill AugustineWichita$8K
- Rebecca WernliWichita$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.